Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761563 · ClinicalTrials.gov registry record
Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease
A clinical trial, sponsored by Xtant Medical.
- Completed
- Registry status
- 15
- Enrollment target
NCT03761563 is a clinical trial that has completed, run by Xtant Medical. The registered enrollment target is 15 participants.
The verdict
NCT03761563 has completed, sponsored by Xtant Medical.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.
Interventions
- DEVICE Fortilink IBF System with TETRAfuse Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2023-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761563
The ClinicalTrials.gov registry entry for NCT03761563 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xtant Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fortilink IBF System with TETRAfuse Technology is the first listed.
NCT03761563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03761563 about?
NCT03761563 is a clinical study titled "Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease". This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.
What is the current status of trial NCT03761563?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2019-02-13. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT03761563?
The interventions under investigation include: Fortilink IBF System with TETRAfuse Technology (DEVICE).
Who is sponsoring clinical trial NCT03761563?
This trial is sponsored by Xtant Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.